Ross A McKinnon Selected Research

Glucuronosyltransferase (UDP Glucuronosyltransferase)

1/2018	Regulation of UDP-Glucuronosyltransferase 2B15 by miR-331-5p in Prostate Cancer Cells Involves Canonical and Noncanonical Target Sites.
1/2017	Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
1/2017	Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
1/2016	Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.
6/2015	Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
5/2015	Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ross A McKinnon Research Topics

Disease

25	Neoplasms (Cancer) 01/2022 - 08/2008
11	Breast Neoplasms (Breast Cancer) 08/2021 - 06/2015
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2014
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2022 - 08/2019
5	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 05/2015
4	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 09/2015
3	Liver Neoplasms (Liver Cancer) 01/2022 - 05/2015
2	Cognitive Dysfunction 03/2022 - 01/2022
2	Schizophrenia (Dementia Praecox) 03/2022 - 01/2022
2	Dysbiosis 01/2022 - 01/2022
2	Lung Neoplasms (Lung Cancer) 01/2022 - 08/2019
2	Hand-Foot Syndrome 01/2022 - 01/2020
2	Chronic Obstructive Pulmonary Disease (COPD) 09/2021 - 11/2020
2	Neutropenia 08/2021 - 06/2012
2	Nausea 01/2020 - 08/2008
2	Vomiting 01/2020 - 08/2008
2	Melanoma (Melanoma, Malignant) 08/2019 - 09/2017
2	Inflammation (Inflammations) 12/2016 - 01/2014
2	Hypercholesterolemia 01/2012 - 03/2010
2	Autism Spectrum Disorder 10/2010 - 12/2009
1	Carcinoma (Carcinomatosis) 01/2022
1	Heart Failure 01/2021
1	Atrial Fibrillation 01/2021
1	Exanthema (Rash) 01/2020
1	Thrombocytopenia (Thrombopenia) 01/2020
1	Treatment-Resistant Schizophrenia 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Adenocarcinoma 01/2018
1	Infections 12/2017

Drug/Important Bio-Agent (IBA)

9	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2014
9	Pharmaceutical PreparationsIBA 01/2022 - 03/2010
8	atezolizumabIBA 03/2022 - 08/2019
7	Immune Checkpoint InhibitorsIBA 03/2022 - 09/2017
7	Biomarkers (Surrogate Marker)IBA 09/2021 - 12/2009
6	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 01/2018 - 05/2015
3	Lapatinib (GW572016)FDA Link 01/2020 - 01/2017
3	AndrogensIBA 01/2018 - 12/2016
3	Messenger RNA (mRNA)IBA 01/2018 - 01/2017
3	AnthracyclinesIBA 08/2017 - 05/2015
3	Proteins (Proteins, Gene)FDA Link 01/2017 - 12/2016
2	Antipsychotic Agents (Antipsychotics)IBA 03/2022 - 01/2022
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 12/2017
2	Proton Pump InhibitorsIBA 01/2022 - 01/2022
2	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 01/2017
2	Uridine Diphosphate (UDP)IBA 09/2021 - 01/2017
2	Histone Deacetylase InhibitorsIBA 02/2021 - 09/2015
2	Cytochrome P-450 CYP2C19IBA 11/2020 - 12/2014
2	human ERBB2 proteinIBA 01/2020 - 01/2020
2	Ado-Trastuzumab EmtansineIBA 01/2020 - 11/2019
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2019
2	pertuzumabIBA 01/2020 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2018
2	Biological ProductsIBA 01/2019 - 12/2009
2	EnzymesIBA 01/2019 - 01/2017
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2018 - 01/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2017 - 05/2016
2	Androgen Receptors (Androgen Receptor)IBA 01/2017 - 09/2015
2	Estrogen ReceptorsIBA 01/2017 - 06/2015
2	Epirubicin (Ellence)FDA LinkGeneric 05/2016 - 05/2015
2	Monoclonal AntibodiesIBA 03/2016 - 12/2015
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2012 - 03/2010
1	AminesIBA 03/2022
1	Trace amine-associated receptor 1IBA 03/2022
1	Metformin (Glucophage)FDA LinkGeneric 01/2022
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	SEP-363856IBA 01/2022
1	Trace Amine-Associated ReceptorsIBA 01/2022
1	AlbuminsIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022
1	GlycosyltransferasesIBA 09/2021
1	abemaciclibIBA 08/2021
1	Butyrates (Butyrate)IBA 02/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Digoxin (Digitek)FDA LinkGeneric 01/2021
1	DiureticsIBA 01/2021
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 11/2020
1	Cytochrome P-450 CYP3AIBA 11/2020
1	Cytochrome P-450 CYP2C9IBA 11/2020
1	Cytochrome P-450 CYP2E1 (CYP2E1)IBA 11/2020
1	Cytochrome P-450 CYP2C8IBA 11/2020
1	Clozapine (Clozaril)FDA LinkGeneric 01/2020
1	taxaneIBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	Capecitabine (Xeloda)FDA Link 01/2020
1	pembrolizumabIBA 08/2019
1	Protein Kinase InhibitorsIBA 01/2019
1	Docetaxel (Taxotere)FDA Link 01/2019
1	3' Untranslated Regions (3' UTR)IBA 01/2018
1	Vancomycin FDA LinkGeneric 12/2017
1	IpilimumabIBA 09/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2017
1	regorafenibIBA 01/2017

Therapy/Procedure

15	Therapeutics 01/2022 - 11/2010
5	Drug Therapy (Chemotherapy) 03/2022 - 08/2008
2	Immunotherapy 01/2022 - 01/2022